GLAXO Stock Overview
Operates as a biopharma company in Pakistan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GlaxoSmithKline Pakistan Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨136.69 |
| 52 Week High | PK₨151.00 |
| 52 Week Low | PK₨68.00 |
| Beta | 0.39 |
| 11 Month Change | -2.02% |
| 3 Month Change | 36.15% |
| 1 Year Change | 72.39% |
| 33 Year Change | -14.98% |
| 5 Year Change | 51.88% |
| Change since IPO | 354.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLAXO | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -2.9% | -5.2% | -3.4% |
| 1Y | 72.4% | 64.9% | 43.9% |
Return vs Industry: GLAXO exceeded the PK Pharmaceuticals industry which returned 64.9% over the past year.
Return vs Market: GLAXO exceeded the PK Market which returned 43.9% over the past year.
Price Volatility
| GLAXO volatility | |
|---|---|
| GLAXO Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PK Market | 8.6% |
| 10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: GLAXO's share price has been volatile over the past 3 months.
Volatility Over Time: GLAXO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,700 | Erum Rahim | www.pk.gsk.com |
GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix.
GlaxoSmithKline Pakistan Limited Fundamentals Summary
| GLAXO fundamental statistics | |
|---|---|
| Market cap | PK₨43.53b |
| Earnings (TTM) | PK₨668.67m |
| Revenue (TTM) | PK₨53.88b |
65.1x
P/E Ratio0.8x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAXO income statement (TTM) | |
|---|---|
| Revenue | PK₨53.88b |
| Cost of Revenue | PK₨49.31b |
| Gross Profit | PK₨4.57b |
| Other Expenses | PK₨3.90b |
| Earnings | PK₨668.67m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 2.10 |
| Gross Margin | 8.49% |
| Net Profit Margin | 1.24% |
| Debt/Equity Ratio | 0% |
How did GLAXO perform over the long term?
See historical performance and comparison